loading page

New understanding of exosomes as a miRNA delivery mechanism has led to advances in RNA cancer treatments
  • Jessica Harris
Jessica Harris
Department of Molecular Medicine, University of San Diego

Corresponding Author:[email protected]

Author Profile


With the introduction of mRNA-based vaccinations and RNA interference techniques like siRNA, a new age of RNA therapeutics has begun. Unfortunately, there are currently no RNA-based therapies for cancer that have been authorized by the FDA. MiRNAs are an exciting new frontier in the fight against cancer since they are RNA molecules. Despite miRNA-based medicines' potential to target numerous pathways, getting to the phase 3 clinical trial is difficult. The difficulty of delivering miRNAs just to the tumor cells that need them has contributed to the delay. This emphasizes the need of a reliable distribution network. In this regard, exosomes are seen as the safest and most efficient cargo delivery vehicles for miRNA-based therapeutics. As an added bonus, a new generation therapy for cancer treatment has been uncovered: harnessing exosomes to release superfluous miRNAs to counteract the tumor's potential to replicate. The latest developments in the use of microRNAs in cancer therapy are discussed, including the transport of miRNAs via exosomes and strategies to overcome the limitations of miRNA-loaded exosomes in clinical settings. MiRNA, microRNA, microRNA delivery system, RNA-based medicines, cancer therapy, exosomes.
16 Nov 2023Submitted to ESS Open Archive
22 Nov 2023Published in ESS Open Archive